177 related articles for article (PubMed ID: 30972974)
1. βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.
Gao R; Kanasaki K; Li J; Kitada M; Okazaki T; Koya D
FEBS Open Bio; 2019 May; 9(5):1029-1038. PubMed ID: 30972974
[TBL] [Abstract][Full Text] [Related]
2. FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway.
Li J; Shi S; Srivastava SP; Kitada M; Nagai T; Nitta K; Kohno M; Kanasaki K; Koya D
Cell Death Dis; 2017 Aug; 8(8):e2965. PubMed ID: 28771231
[TBL] [Abstract][Full Text] [Related]
3. Endothelial FGFR1 (Fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice.
Li J; Liu H; Srivastava SP; Hu Q; Gao R; Li S; Kitada M; Wu G; Koya D; Kanasaki K
Hypertension; 2020 Dec; 76(6):1935-1944. PubMed ID: 33131311
[TBL] [Abstract][Full Text] [Related]
4. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.
Nagai T; Kanasaki M; Srivastava SP; Nakamura Y; Ishigaki Y; Kitada M; Shi S; Kanasaki K; Koya D
Biomed Res Int; 2014; 2014():696475. PubMed ID: 24783220
[TBL] [Abstract][Full Text] [Related]
5. FGFR1 is essential for N-acetyl-seryl-aspartyl-lysyl-proline regulation of mitochondrial dynamics by upregulating microRNA let-7b-5p.
Hu Q; Li J; Nitta K; Kitada M; Nagai T; Kanasaki K; Koya D
Biochem Biophys Res Commun; 2018 Jan; 495(3):2214-2220. PubMed ID: 29269295
[TBL] [Abstract][Full Text] [Related]
6. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.
Srivastava SP; Shi S; Kanasaki M; Nagai T; Kitada M; He J; Nakamura Y; Ishigaki Y; Kanasaki K; Koya D
Sci Rep; 2016 Jul; 6():29884. PubMed ID: 27425816
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.
Zhang L; Xu LM; Chen YW; Ni QW; Zhou M; Qu CY; Zhang Y
World J Gastroenterol; 2012 Oct; 18(37):5283-8. PubMed ID: 23066324
[TBL] [Abstract][Full Text] [Related]
8. The Interaction of Apelin and FGFR1 Ameliorated the Kidney Fibrosis through Suppression of TGF
Gao R; Wu Y; Yang Q; Chen L; Chen J; Wang B; Liu Z; Jin J; Li J; Wu G
Oxid Med Cell Longev; 2023; 2023():5012474. PubMed ID: 36785790
[TBL] [Abstract][Full Text] [Related]
9. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
10. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses
Shi Y; Zhou M; Yan J; Gong Z; Wu J; Chen Y; Chen Y
Front Pharmacol; 2020; 11():593. PubMed ID: 32435194
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.
Kanasaki K
J Diabetes Investig; 2020 May; 11(3):516-526. PubMed ID: 31997585
[TBL] [Abstract][Full Text] [Related]
12. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
Zhang Y; Zhang ZG; Chopp M; Meng Y; Zhang L; Mahmood A; Xiong Y
J Neurosurg; 2017 Mar; 126(3):782-795. PubMed ID: 28245754
[TBL] [Abstract][Full Text] [Related]
13. microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney.
Srivastava SP; Hedayat AF; Kanasaki K; Goodwin JE
Front Pharmacol; 2019; 10():904. PubMed ID: 31474862
[TBL] [Abstract][Full Text] [Related]
14. [Regulating effect of N-acetyl-seryl-aspartyl-lysyl-proline on activation of c-jun N-terminal kinase pathway in rats with silicosis].
Wei ZQ; Yu WY; Feng HL; Ma WD; Li ZG; Xu H; Wang RM; Yang F
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2013 May; 31(5):335-40. PubMed ID: 23803521
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
Zhang L; Chopp M; Teng H; Ding G; Jiang Q; Yang XP; Rhaleb NE; Zhang ZG
Stroke; 2014 Apr; 45(4):1108-14. PubMed ID: 24549864
[TBL] [Abstract][Full Text] [Related]
16. Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells.
Iwamoto N; Xano HJ; Yoshioka T; Shiraga H; Nitta K; Muraki T; Ito K
Life Sci; 2000 Mar; 66(15):PL221-6. PubMed ID: 11210724
[TBL] [Abstract][Full Text] [Related]
17. [Effect of N-acetyl-seryl-aspartyl-lysyl-proline on regulation of expression of ras-raf-ERK1/2 signal transduction pathway in lung of rats with silicosis].
Tian JR; Yang F; Li DD; Zhang LJ; Wei ZQ; Feng HL; Li ZG; Wang RM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2010 Oct; 28(10):760-5. PubMed ID: 21126429
[TBL] [Abstract][Full Text] [Related]
18. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Nitta K; Shi S; Nagai T; Kanasaki M; Kitada M; Srivastava SP; Haneda M; Kanasaki K; Koya D
Biomed Res Int; 2016; 2016():9172157. PubMed ID: 27088094
[TBL] [Abstract][Full Text] [Related]
19. [Anti-fibrotic role of AcSDKP through inhibition of P38MAPK pathway activity mediated transforming growth beta receptors in rat with silicosis].
Wei Z; Sun Y; Cheng H; Ma W; Xu H; Li Q; Zhang L; Wang R; Yang F
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2014 May; 32(5):340-7. PubMed ID: 25169087
[TBL] [Abstract][Full Text] [Related]
20. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.
Agrawal A; Parlee S; Perez-Tilve D; Li P; Pan J; Mroz PA; Kruse Hansen AM; Andersen B; Finan B; Kharitonenkov A; DiMarchi RD
Mol Metab; 2018 Jul; 13():45-55. PubMed ID: 29789271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
